Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Atherosclerosis ; 144(1): 135-50, 1999 May.
Artigo em Inglês | MEDLINE | ID: mdl-10381287

RESUMO

Revascularization by percutaneous transluminal coronary angioplasty is limited in the long-term by restenosis, which is luminal renarrowing in the first 6 months after the procedure. Smooth muscle cell proliferation is thought to be an important factor in restenosis; this leads to neointima formation and arterial lumen narrowing. Local therapy delivered perivascularly may have an effect on events in the neointima and reduce restenosis. The effect of delivering expression vector plasmids for senescent cell-derived inhibitor SDI-1, which regulates cell proliferation, and its antisense, into the perivascular tissue of injured arteries was investigated in a porcine arterial injury model using a needle injection catheter. Transfection efficiency, biological effect and plasmid dissemination were evaluated in arterial and organ tissue sections between 2 days and 4 months. A limited number of adventitial, medial and neointimal cells were transfected up to 4 months. sdi gene transfer did not result in a change in neointima. Transfer of antisense sdi resulted in an increase in neointima after 3 weeks. No DNA plasmid was detected in control tissues. Liposomally-mediated adventitial local gene delivery is feasible and safe using the needle injection catheter in a porcine model. A limited number of cells was transfected, with expression of transfected genes up to 4 months after delivery. A transient biological effect with increased neointima was observed after delivery of the antisense sdi gene.


Assuntos
Terapia Genética/métodos , Músculo Liso Vascular/citologia , Plasmídeos/administração & dosagem , Túnica Íntima/citologia , Análise de Variância , Animais , Sequência de Bases , Western Blotting , Cateterismo , Ciclo Celular , Divisão Celular , Células Cultivadas , DNA/análise , Modelos Animais de Doenças , Artéria Femoral/citologia , Artéria Femoral/lesões , Expressão Gênica , Humanos , Imuno-Histoquímica , Injeções Intralesionais/instrumentação , Dados de Sequência Molecular , Plasmídeos/genética , Reação em Cadeia da Polimerase , Sensibilidade e Especificidade , Suínos , Porco Miniatura , Fatores de Tempo
3.
J Mol Med (Berl) ; 75(11-12): 820-8, 1997.
Artigo em Inglês | MEDLINE | ID: mdl-9428612

RESUMO

Constitutive, high-level expression of the potentially therapeutic WAF-1/CIP-1/SDI-1 gene is incompatible with cell growth. A promoter conversion retroviral vector carrying the WAF-1/CIP-1/SDI-1 gene under the transcriptional control of the glucocorticoid inducible promoter of mouse mammary tumor virus was used to infect human bladder carcinoma or feline kidney cells. Reduced cell growth due to a greater proportion of cells being in the G0/G1 phase of the cell cycle was observed when WAF-1/CIP-1/SDI-1 expression was activated by addition of glucocorticoid hormone. This system demonstrates the potential long-term therapeutic use of WAF-1/CIP-1/SDI-1 delivered by retroviral vectors for inhibiting the growth of rapidly proliferating cells. Moreover, the conditional expression of genes such as WAF-1/CIP-1/SDI-1 from such retroviral vectors may facilitate analysis of their function.


Assuntos
Ciclinas/genética , Vetores Genéticos/genética , Vírus da Leucemia Murina/genética , Vírus do Tumor Mamário do Camundongo/genética , Regiões Promotoras Genéticas , Animais , Gatos , Divisão Celular/genética , Linhagem Celular , Inibidor de Quinase Dependente de Ciclina p21 , Ciclinas/biossíntese , Dexametasona/farmacologia , Regulação da Expressão Gênica/efeitos dos fármacos , Vetores Genéticos/síntese química , Vetores Genéticos/metabolismo , Humanos , Camundongos , Células Tumorais Cultivadas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...